List of Revvity Research & Development Customers
Waltham, 2451, MA,
United States
Since 2010, our global team of researchers has been studying Revvity Research & Development customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Revvity Research & Development for Clinical Trial Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Revvity Research & Development for Clinical Trial Management include: Eli Lilly, a United States based Life Sciences organisation with 50605 employees and revenues of $65.18 billion, Merck Group, a Germany based Life Sciences organisation with 62557 employees and revenues of $24.93 billion, Camurus, a Sweden based Life Sciences organisation with 250 employees and revenues of $66.0 million and many others.
Contact us if you need a completed and verified list of companies using Revvity Research & Development, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Revvity Research & Development customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
Camurus | Life Sciences | 250 | $66M | Sweden | Revvity | Revvity Research & Development | Clinical Trial Management | 2023 | n/a |
In 2023, Camurus implemented Revvity Research & Development. Camurus adopted Revvity Signals Notebook to streamline R&D workflows across chemistry and biology teams in Sweden, improving data accuracy, traceability and cross-team collaboration, and Revvity Research & Development appears within the broader Clinical Trial Management context as part of the Signals Research suite.
The implementation centered on electronic laboratory notebook capabilities, structured experiment capture, audit trails and version control to enforce traceability across chemical and biological data sets. Configuration work focused on templates for experimental records, access controls for project based data segregation and collaboration features to enable cross functional review and annotation, aligning with standard laboratory informatics and study documentation workflows.
Operational coverage explicitly includes Camurus chemistry and biology teams in Sweden, with the Signals Research suite providing core data capture and collaboration. Given Camurus use of the broader Signals Research suite, potential usage of Signals Clinical CTMS capabilities for study data management is plausible, however module usage for CTMS is inferred rather than confirmed.
Governance emphasis in the rollout included data stewardship, role based permissions and lifecycle controls to maintain data integrity and traceability across studies. Reported outcomes from the deployment are improved data accuracy, stronger traceability and enhanced cross team collaboration within R&D workflows.
|
 |
Eli Lilly | Life Sciences | 50605 | $65.2B | United States | Revvity | Revvity Research & Development | Clinical Trial Management | 2025 | n/a |
In 2025, Eli Lilly implemented Revvity Research & Development to centralize R&D data capture and automation across its research organization in the United States. The deployment is aligned to the Clinical Trial Management category and incorporates Revvity Signals capabilities to support regulated study and lab workflows.
The implementation used Revvity Signals with the Signals Notebook capability to standardize experiment documentation, automate molecule registration workflows, and strengthen GxP compliance controls. Usage of the Clinical Trial Management module Signals Clinical is inferred from Lilly's enterprise engagement with the broader Revvity Signals suite, and Revvity Research & Development was configured to enforce structured data capture and electronic records for study artifacts.
Operational scope focused on Eli Lilly research and development teams in the United States, shifting molecule registration and handoff processes from manual touch points to automated, system-driven transitions. Governance changes emphasized centralized data stewardship, standardized registration workflows, and compliance-oriented documentation to reduce manual errors and accelerate data handoffs, outcomes that were explicitly reported in the implementation notes.
|
 |
Merck Group | Life Sciences | 62557 | $24.9B | Germany | Revvity | Revvity Research & Development | Clinical Trial Management | 2024 | n/a |
In 2024, Merck Group implemented Revvity Research & Development in an R&D deployment associated with EMD Electronics, part of Merck KGaA, focused on materials research activities in Germany. The engagement is recorded under the Clinical Trial Management category for cataloging purposes, while the technical deployment served laboratory informatics and experimental data consolidation rather than explicit clinical operations.
The implementation centered on Revvity Signals Notebook as the primary experimental recording and knowledge capture module, integrated with Scitara to unify instrument and experimental data streams. Revvity Research & Development was configured to capture structured experimental records, link instrument outputs, and enable downstream analytics, supporting AI and ML driven insight generation for materials R&D workflows.
Integrations explicitly included Scitara for instrument connectivity and data ingestion, creating a single scientific data layer for lab operations and materials research teams within Germany. Operational coverage targeted laboratory R&D functions including experiment capture, data provenance, and analytics pipelines, aligning research data management with analytics consumption points.
Governance and rollout focused on lab informatics process alignment and research data governance to support reproducibility and traceability, with configuration controls applied to Signals Notebook records and instrument data mappings. Any use of Revvity Signals Clinical CTMS modules for clinical trial management elsewhere in the Merck organization is not explicit in the source and therefore module usage outside this R&D context is inferred rather than confirmed.
|
Buyer Intent: Companies Evaluating Revvity Research & Development
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||